Citizens JMP raised the firm’s price target on Zevra Therapeutics (ZVRA) to $18 from $17 and keeps an Outperform rating on the shares. Zevra reported Q4 revenue that was significantly ahead of consensus estimates, driven by MIPLYFFA U.S. sales, and the MIPLYFFA launch continues to exceed expectations with prescription enrollment forms submitted for 109 patients as of December 31, the analyst tells investors in a research note. The firm expects continued patient additions through 2025, driven by solid awareness of MIPLYFFA in the Niemann-Pick disease type C community.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZVRA:
- Zevra Therapeutics: Strong Financial Performance and Promising Growth Prospects Justify Buy Rating
- Zevra Therapeutics: Strong Financial Performance and Strategic Growth Justify Buy Rating
- Zevra Therapeutics Reports 2024 Financial Results and Strategic Progress
- Zevra Therapeutics reports Q4 EPS (67c), consensus (40c)
- Zevra Therapeutics: Strategic Growth and Financial Strength Drive Buy Rating
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue